The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The DREAMM project is investigating whether point of care tests within a diagnostic and treatment algorithm together with support and additional training of laboratory and clinical staff will reduce two and ten week all-cause mortality of HIV-associated meningo-encephalitis in LMICs.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
The study will be conducted at three sites in southern, eastern and central Sub-Saharan Africa:
Amana and Mwananyamala hospitals, Dar Es Salaam, Tanzania
Kamuzu Central Hospital (KCH), Lilongwe, Malawi
Hôpital Central Yaoundé (HCY), Yaoundé, Cameroon
Adult HIV positive patients presenting to hospital at DREAMM study sites with a first episode of suspected meningo-encephalitis will be eligible for the study.
In the context of HIV, patients with headache, and/or seizure, and/or reduced level of consciousness/abnormal behaviour and/or focal neurology require investigation for meningo-encephalitis.
Consecutive patients > 18 years with 1st episode of suspected meningo- encephalitis
Known to be HIV positive or willing to undertake an HIV test
Willing to agree to participate in the study
Patients presenting with suspected relapse of HIV-associated meningo-encephalitis
Cerebral malaria confirmed on point of care test or thick/thin blood film, by clinical evaluation and further investigation, as required
HIV negative patients
Pregnant or lactating patients
Patients who are HIV negative or are diagnosed with cerebral malaria on hospital admission or after initial investigation will be excluded or withdrawn from the DREAMM study.
AIDS-Related Opportunistic Infections
Central Nervous System Diseases
Nervous System Diseases
RNA Virus Infections
Immunologic Deficiency Syndromes
Immune System Diseases
Central Nervous System Fungal Infections
Central Nervous System Infections
Central Nervous System Viral Diseases